November's wave of FDA oncology approvals signals the industry's shift toward platform-based precision therapies over broad-spectrum approaches. The global anticancer drug market now values immunotherapies at over 45 percent of total cancer drug revenues, reflecting investor confidence in technologies that engineer specific biological outcomes.

Companies deploying proprietary platforms to target previously undruggable proteins are capturing premium valuations as the sector pivots toward modularity and rapid reuse of validated mechanisms, creating momentum for GT Biopharma, Inc, Erasca, Inc, Foghorn Therapeutics Inc, OmniAb, Inc and Recursion Pharmaceuticals Inc.

The US oncology market is projected to surge from USD 81 billion in 2025 to USD 212 billion by 2034, with monoclonal antibodies and cell therapies leading growth at double-digit rates. Platform technologies now account for 60 percent of total pharma projected pipeline value, creating optimal conditions for companies with validated platforms to capture multiple therapeutic opportunities while reducing development timelines.

GT Biopharma recently reported continued progress with its phase I clinical trial of GTB-3650, which has now advanced into Cohort 4 at a dose level of 10μg/kg/day. The company is developing innovative immunotherapy treatments designed to combat some of the world's most challenging cancer types using its proprietary natural killer cell engager TriKE platform technology.

The phase I dose escalation study is evaluating GTB-3650 in patients battling relapsed or refractory blood cancers that express the CD33 protein, specifically Acute Myeloid Leukemia (AML) and high-risk myelodysplastic syndrome (MDS). These represent some of the most difficult cancer cases to treat, involving patients whose disease either came back after initial therapy or never responded to conventional treatment options.

GTB-3650 works by stimulating the patient's natural killer cells, a type of immune cell that naturally hunts down and destroys abnormal cells, to specifically target cancer cells. Patients receive the therapy through continuous infusions following a structured schedule: two weeks of treatment followed by two weeks of rest, repeating this cycle for up to four months based on how they respond.

"We are highly encouraged by the continued progress of our phase I clinical trial evaluating GTB-3650 in cancer patients, which has now advanced to Cohort 4 at a dose level of 10 µg/kg/day. We look forward to assessing higher doses, as we are now approaching the efficacy range predicted by preclinical in vivo leukemia models, and we plan to share the next trial update in the first quarter of 2026," said Michael Breen, Executive Chairman and CEO, GT Biopharma.